Helsinn and Immedica enter exclusive partnership for commercialization of cancer supportive care products in core European markets
Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases, and Immedica Pharma AB, a pharmaceutical company focused on commercialisation of rare and specialty care products, today announce that the companies have entered an exclusive long-term license and distribution agreement for the commercialisation of two cancer supportive care products indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV) in core European markets : AKYNZEO® (Netupitant-Palonosetron fixed combination) and ALOXI® (Palonosetron). Under the licence and distribution agreement Immedica will commercialise AKYNZEO® in Portugal, Spain, France, Switzerland, the Netherlands, Belgium, Luxembourg and Liechtenstein, ALOXI® in Switzerland, Belgium, Liechtenstein.
Read moreNews
Impilo’s portfolio company Decon acquires Acekare – a French-based manufacturer and distributor of mobility assistance solutions
The acquisition of Acekare marks an important step in Decon’s strategic ambition to build a leading European niche mobility platform by adding a complementary product company to its existing offering and establishing a direct presence in the French market
Impilo’s portfolio company Pelago Bioscience acquires RG Discovery, forming an integrated drug discovery partner spanning biology and chemistry
Impilo’s portfolio company Pelago Bioscience acquires RG Discovery, forming an integrated drug discovery partner spanning biology and chemistry
Impilo completes the acquisition of Oticon Medical
We are pleased to announce that Impilo has today completed the acquisition of Oticon Medical from Demant A/S. This marks the first investment in our recently raised Fund II.